The Adalimumab Biosimilar Market is developing rapidly as pharmaceutical companies expand their biosimilar portfolios and healthcare systems seek opportunities to reduce treatment costs. The market was valued at USD 4.9 billion in 2025 and is forecast to reach USD 15.0 billion by 2035 at an estimated CAGR of 11.8%.

By indication, the market includes rheumatoid arthritis, Crohn's disease, psoriasis, ulcerative colitis, and ankylosing spondylitis. These therapeutic areas represent significant opportunities because of the increasing prevalence of chronic inflammatory and autoimmune disorders.

The dosage-form segment includes injectable products, prefilled syringes, single-dose vials, and multi-dose vials. Distribution channels consist of hospital pharmacies, retail pharmacies, and online pharmacies. Hospitals, homecare settings, and specialty clinics represent important end-user segments.

The competitive landscape includes major companies such as Amgen, AbbVie, Samsung Bioepis, Boehringer Ingelheim, Sandoz, Pfizer, Mylan, Teva, Fresenius Kabi, Celltrion, Intas Pharmaceuticals, Hikma Pharmaceuticals, and others.

North America maintains a strong position, while Europe benefits from biosimilar acceptance and supportive regulatory conditions. Asia-Pacific is emerging as a high-growth region due to improving healthcare access and biotechnology investment.

Patent expirations, competitive pricing, regulatory approvals, and manufacturing advancements are expected to continue influencing competition and market positioning.